Advertisement

Topics

Sanofi Genzyme’s foray into Indian MS market should be met with caution, says GlobalData

09:52 EDT 28 Aug 2018 | EPM Magazine

Sanofi Genzyme — specialty care global business unit of French pharma company Sanofi — has launched its multiple sclerosis (MS) drug in India, however, according to GlobalData, it should be cautious of fierce generic competition…

Original Article: Sanofi Genzyme’s foray into Indian MS market should be met with caution, says GlobalData

NEXT ARTICLE

More From BioPortfolio on "Sanofi Genzyme’s foray into Indian MS market should be met with caution, says GlobalData"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Multiple Sclerosis MS
Multiple sclerosis (MS) is the most common disabling neurological condition affecting 100,000 young adults in the UK. The condition results from autoimmune damage to myelin, causing interference in nerve signaling. Symptoms experienced depend on the pa...